Grant: Engage Plus Grants Program
Brock University
$10,000.00
Further Optimization and scale-up of high-yielding stereoselective methodologies for the synthesis of Active Pharmaceutical Agents (API)
FY 2014-15
Summary
The proposed collaborative project with Alphora Research involves the development of synthetic processes for manufacturing precursors for a group of chemical compounds called halichondrin polycyclic macrolides, which have potential as cancer drugs. These anti-tumour substances are related to halichondrin B, a natural product that was isolated from a marine sponge. Health Canada and the FDA have recently approved the fully synthetic analog eribulin for treatment of certain metastatic breast cancers; however, the manufacturing process is not yet efficient for this and related substances. Following up with our recent Engage Grant, we are continuing our efforts in improving the methodologies for some of the steps in the preparation of this medicinally important group of compounds.
Program
Engage Plus Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
471021-2014
Name nom
Dudding, Travis
Department département
Chemistry
Organization id
22
Institution établissement
Brock University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
10000
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Further Optimization and scale-up of high-yielding stereoselective methodologies for the synthesis of Active Pharmaceutical Agents (API)
Keyword
NSERC
Application summary
The proposed collaborative project with Alphora Research involves the development of synthetic processes for manufacturing precursors for a group of chemical compounds called halichondrin polycyclic macrolides, which have potential as cancer drugs. These anti-tumour substances are related to halichondrin B, a natural product that was isolated from a marine sponge. Health Canada and the FDA have recently approved the fully synthetic analog eribulin for treatment of certain metastatic breast cancers; however, the manufacturing process is not yet efficient for this and related substances. Following up with our recent Engage Grant, we are continuing our efforts in improving the methodologies for some of the steps in the preparation of this medicinally important group of compounds.
